Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 29:10:1125687.
doi: 10.3389/fcvm.2023.1125687. eCollection 2023.

Inflammation as a therapeutic target in heart failure with preserved ejection fraction

Zhen Hui Peh  1 , Adel Dihoum  2 , Dana Hutton  1 , J Simon C Arthur  3 , Graham Rena  4 , Faisel Khan  5 , Chim C Lang  2 , Ify R Mordi  2
Affiliations
Review

Inflammation as a therapeutic target in heart failure with preserved ejection fraction

Zhen Hui Peh et al. Front Cardiovasc Med. .

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.

Keywords: HFpEF; cardiometabolic; heart failure; inflammation; interleukins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Common HFpEF phenotypes.
Figure 2
Figure 2
The innate immune system and HFpEF.
See this image and copyright information in PMC

References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42(36):3599–726. 10.1093/eurheartj/ehab368 - DOI - PubMed
    1. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. (2013) 10(4):401–10. 10.1007/s11897-013-0155-7 - DOI - PMC - PubMed
    1. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. (2018) 39(30):2780–92. 10.1093/eurheartj/ehy301 - DOI - PubMed
    1. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. (2014) 370(15):1383–92. 10.1056/NEJMoa1313731 - DOI - PubMed
    1. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. (2019) 381(17):1609–20. 10.1056/NEJMoa1908655 - DOI - PubMed